|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Greenberg PA, Hortobagyi GN, Smith TL,
Ziegler LD, Frye DK and Buzdar AU: Long-term follow-up of patients
with complete remission following combination chemotherapy for
metastatic breast cancer. J Clin Oncol. 14:2197–2205.
1996.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fidler IJ: Metastasis: Quantitative
analysis of distribution and fate of tumor emboli labeled with 125
I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst. 45:773–782.
1970.PubMed/NCBI
|
|
4
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mego M, Mani SA and Cristofanilli M:
Molecular mechanisms of metastasis in breast cancer-clinical
applications. Nat Rev Clin Oncol. 7:693–701. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW and Hayes DF: Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J
Med. 351:781–791. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Giuliano M, Giordano A, Jackson S, Hess
KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De
Laurentiis M, et al: Circulating tumor cells as prognostic and
predictive markers in metastatic breast cancer patients receiving
first-line systemic treatment. Breast Cancer Res.
13(R67)2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ignatiadis M, Kallergi G, Ntoulia M,
Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E,
Lianidou E, Georgoulias V and Mavroudis D: Prognostic value of the
molecular detection of circulating tumor cells using a multimarker
reverse transcription-PCR assay for cytokeratin 19, mammaglobin A,
and HER2 in early breast cancer. Clin Cancer Res. 14:2593–2600.
2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lucci A, Hall CS, Lodhi AK, Bhattacharyya
A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM and Krishnamurthy S:
Circulating tumour cells in non-metastatic breast cancer: A
prospective study. Lancet Oncol. 13:688–695. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lv Q, Gong L, Zhang T, Ye J, Chai L, Ni C
and Mao Y: Prognostic value of circulating tumor cells in
metastatic breast cancer: A systemic review and meta-analysis. Clin
Transl Oncol. 18:322–330. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang L, Riethdorf S, Wu G, Wang T, Yang
K, Peng G, Liu J and Pantel K: Meta-analysis of the prognostic
value of circulating tumor cells in breast cancer. Clin Cancer Res.
18:5701–5710. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Enderling H, Hlatky L and Hahnfeldt P:
Migration rules: Tumours are conglomerates of self-metastases. Br J
Cancer. 100:1917–1925. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kim MY, Oskarsson T, Acharyya S, Nguyen
DX, Zhang XH, Norton L and Massague J: Tumor self-seeding by
circulating cancer cells. Cell. 139:1315–1326. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mego M, Mani SA, Lee BN, Li C, Evans KW,
Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, et al:
Expression of epithelial-mesenchymal transition-inducing
transcription factors in primary breast cancer: The effect of
neoadjuvant therapy. Int J Cancer. 130:808–816. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cancer Genome Atlas, Network:
Comprehensive molecular portraits of human breast tumours. Nature
490: 61-70, 2012.
|
|
17
|
Lefebvre C, Bachelot T, Filleron T,
Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M,
Lacroix-Triki M, et al: Mutational profile of metastatic breast
cancers: A retrospective analysis. PLoS Med.
13(e1002201)2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bingham C, Fernandez SV, Fittipaldi P,
Dempsey PW, Ruth KJ, Cristofanilli M and Katherine Alpaugh R:
Mutational studies on single circulating tumor cells isolated from
the blood of inflammatory breast cancer patients. Breast Cancer Res
Treat. 163:219–230. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bredemeier M, Kasimir-Bauer S, Kolberg HC,
Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M,
Kimmig R and Aktas B: Comparison of the PI3KCA pathway in
circulating tumor cells and corresponding tumor tissue of patients
with metastatic breast cancer. Mol Med Rep. 15:2957–2968.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Magbanua MJM, Rugo HS, Wolf DM, Hauranieh
L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, et al:
Expanded genomic profiling of circulating tumor cells in metastatic
breast cancer patients to assess biomarker status and biology over
time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res.
24:1486–1499. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Paoletti C, Cani AK, Larios JM, Hovelson
DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, et al:
Comprehensive mutation and copy number profiling in archived
circulating breast cancer tumor cells documents heterogeneous
resistance mechanisms. Cancer Res. 78:1110–1122. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mego M, Karaba M, Minarik G, Benca J,
Silvia J, Sedlackova T, Manasova D, Kalavska K, Pindak D,
Cristofanilli M, et al: Circulating tumor cells with
epithelial-to-mesenchymal transition phenotypes associated with
inferior outcomes in primary breast cancer. Anticancer Res.
39:1829–1837. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cierna Z, Mego M, Janega P, Karaba M,
Minarik G, Benca J, Sedlackova T, Cingelova S, Gronesova P,
Manasova D, et al: Matrix metalloproteinase 1 and circulating tumor
cells in early breast cancer. BMC Cancer. 14(472)2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mego M, Karaba M, Minarik G, Benca J,
Sedlackova T, Tothova L, Vlkova B, Cierna Z, Janega P, Luha J, et
al: Relationship between circulating tumor cells, blood
coagulation, and urokinase-plasminogen-activator system in early
breast cancer patients. Breast J. 21:155–160. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29(e45)2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
NCSS 2007 Update (Version 1). NCSS, LLC,
Kaysville, Utah, 2007. https://www.ncss.com/download/ncss/updates/ncss-2007-v1/.
Accessed August 8, 2019.
|
|
27
|
Stephens PJ, Tarpey PS, Davies H, Van Loo
P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell
GR, et al: The landscape of cancer genes and mutational processes
in breast cancer. Nature. 486:400–404. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chu IM, Hengst L and Slingerland JM: The
Cdk inhibitor p27 in human cancer: Prognostic potential and
relevance to anticancer therapy. Nature Rev Cancer. 8:253–267.
2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Santarpia L, Bottai G, Kelly CM, Gyorffy
B, Szekely B and Pusztai L: Deciphering and targeting oncogenic
mutations and pathways in breast cancer. Oncologist. 21:1063–1078.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
King MC, Marks JH and Mandell JB: New York
Breast Cancer Study Group: Breast and ovarian cancer risks due to
inherited mutations in BRCA1 and BRCA2. Science. 302:643–646.
2003.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Erturk E, Cecener G, Tezcan G, Egeli U,
Tunca B, Gokgoz S, Tolunay S and Tasdelen I: BRCA mutations cause
reduction in miR-200c expression in triple negative breast cancer.
Gene. 556:163–169. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Heerma van Voss MR, van der Groep P, Bart
J, van der Wall E and van Diest PJ: Lympho-vascular invasion in
BRCA related breast cancer compared to sporadic controls. BMC
Cancer. 10(145)2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bystricky B, Cierna Z, Sieberova G, Janega
P, Karaba M, Minarik G, Benca J, Sedlackova T, Jurisova S,
Gronesova P, et al: Relationship between circulating tumor cells
and annexin A2 in early breast cancer patients. Anticancer Res.
37:2727–2734. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Dawood S, Broglio K, Valero V, Reuben J,
Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H and
Cristofanilli M: Circulating tumor cells in metastatic breast
cancer: From prognostic stratification to modification of the
staging system? Cancer. 113:2422–2430. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kim K, Lu Z and Hay ED: Direct evidence
for a role of beta-catenin/LEF-1 signalling pathway in induction of
EMT. Cell Biol Int. 26:463–476. 2002.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nawshad A, Lagamba D, Polad A and Hay ED:
Transforming growth factor-beta signaling during
epithelial-mesenchymal transformation: Implications for
embryogenesis and tumor metastasis. Cells Tissues Organs.
179:11–23. 2005.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Busch EL, Hornick JL, Umeton R, Albayrak
A, Lindeman NI, MacConaill LE, Garcia EP, Ducar M and Rebbeck TR:
Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13
anatomic sites. Oncotarget. 8:85680–85691. 2017.PubMed/NCBI View Article : Google Scholar
|
